Newsroom

ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has agreed to INTENT’s Initial Pediatric Study Plan (iPSP) for PEP Biologic™ under IND 019567, supporting the company’s request for a full pediatric waiver for its forthcoming Biologics License Applicati...

DUBLIN--(BUSINESS WIRE)--The "Floating Hotels Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Floating Hotels Market, valued at USD 4.83 billion in 2025, is projected to grow to USD 5.19 billion in 2026 and further expand to USD 8.03 billion by 2032, reflecting a steady CAGR of 7.50%. Positioned at the intersection of maritime engineering and hospitality innovation, floating hotels offer a unique proposition by integrating advanced vessel architectur...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Kardium Inc., an emerging leader in advanced solutions for atrial fibrillation, is proud to announce the publication of the PULSAR clinical trial results in the Journal of the American College of Cardiology (JACC). This landmark study evaluated the Globe® Pulsed Field System by Kardium for the treatment of paroxysmal atrial fibrillation (PAF). The multicenter pivotal trial demonstrated that the Globe System achieved durable pulmonary vein isolation...

SAN FRANCISCO--(BUSINESS WIRE)--BIOMAKERS raised an additional $8M to scale its AI-native precision oncology platform, accelerating drug and diagnostic development....

SEATTLE--(BUSINESS WIRE)--Lighthouse today announced the launch of LighthouseIQ, a next-generation intelligence platform and AI application suite....

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications. Galderma welcomes the clarity provided by the arbitral tr...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Clean Edge Smart Grid Infrastructure UCITS ETF 20.01.2026 GRDU.LN IE000J80JTL1 22,375,002.00 USD 1,217,769,948.49 54.425  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Alerian Disruptive Technology Real Estate UCITS ETF 20.01.2026 LANDXEN.LN IE000C75IMX8 22,412.00 USD 423,682.22 18.904  ...

MINNEAPOLIS--(BUSINESS WIRE)--For a twelfth year, Xcel Energy has been honored as one of the World’s Most Admired Companies by Fortune magazine....

LONDON--(BUSINESS WIRE)--  DMO-TAS067/3616/001   The Minster Building21 Mincing LaneLondonEC3R 7AG T 020 7862 6500F 020 7862 6509www.dmo.gov.uk         A010\26 21 January 2026   PRESS NOTICE   RESULT OF THE POST-AUCTION OPTION FACILITY 4% TREASURY GILT 2029   An additional £1,187.499 million nominal of 4% Treasury Gilt 2029 (ISIN Code: GB00BVP99566) will be created for settlement on 22 January 2026 in respect of the amount purchased by the Gilt-edged Market Makers and investors during the Post-...